MEA CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells and Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, and Fourth Generation CAR-T Cells), Targeted Antigens (Antigens On Solid Tumors, Antigens On Hematologic Malignancies, and Others), Brand (Yescarta, Kymriah, Tecartus, and Others), Therapeutic Application (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukaemia (ALL), Mantle Cell Lymphoma, Multiple Myeloma, Hematologic Malignancies, Lung Cancer, Chronic Lymphocytic Leukemia, Gastric Cancer, Pancreatic Cancer, Breast Cancer, and Others), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospitals Pharmacy and Others)- Industry Trends and Forecast to 2031.
MEA CAR-T Cell Therapy Treatment Market Analysis and Size
The rising prevalence of cancer in the MEA region is a key driver for the Car-T cell therapy treatment market, creating a growing need for more effective treatments. However, the high cost of Car-T cell therapy presents a significant barrier, potentially limiting its accessibility. On the bright side, there is an opportunity for market growth through the region's increasing focus on healthcare infrastructure development and medical tourism, particularly in countries like Singapore. Nevertheless, a major challenge is the requirement for extensive Research and clinical trials to establish the long-term efficacy and safety of Car-T cell therapy in this region.
Data Bridge Market Research analyzes that the MEA CAR-T cell therapy treatment market is expected to reach USD 105.69 million by 2031, growing at a CAGR of 30.7% in the forecast period of 2027 to 2031.
|
Report Metric
|
Details
|
|
Forecast Period
|
2027 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Product (Autologous CAR-T Cells and Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, and Fourth Generation CAR-T Cells), Targeted Antigens (Antigens On Solid Tumors, Antigens On Hematologic Malignancies, and Others), Brand (Yescarta, Kymriah, Tecartus, and Others), Therapeutic Application (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukaemia (ALL), Mantle Cell Lymphoma, Multiple Myeloma, Hematologic Malignancies, Lung Cancer, Chronic Lymphocytic Leukemia, Gastric Cancer, Pancreatic Cancer, Breast Cancer, and Others), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospitals Pharmacy and Others)
|
|
Countries Covered
|
Saudi Arabia, South Africa, U.A.E., Israel, Kuwait, Egypt and Rest of Middle East and Africa
|
|
Market Players Covered
|
Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Johnson & Johnson Services, Inc., among others
|
Market Definition
CAR-T cell therapy or chimeric antigen receptor T cells are those T cells which are genetically engineered in order to produce an artificial T-cell receptor which can be used as an immunotherapy for the treatment of various cancers. Chimeric antigen receptors are those receptor proteins that have been engineered in the laboratories to provide the T-cells with the novel ability to target a specific protein. These receptors are chimeric because they are combined with both antigen-binding and T-cell activating functions into a single receptor. Once the CAR-T cells infused in the patient’s body then they act as a “living cell” which has the ability or designed in such a way that they can kill the harmful cancer cells without affecting the healthy cells. The CAR-T cells when comes in contact with the targeted antigen on a cell, CAR-T cells binds with it and becomes activated and multiply to become cytotoxic.
MEA CAR-T Cell Therapy Treatment Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Prevalence of Cancer and other Target Diseases
Cancer is a leading cause of morbidity and mortality worldwide, and the incidence of cancer is rising in these regions due to factors such as population growth, aging, and lifestyle changes. Additionally, there is a growing burden of other target diseases, such as hematological disorders, which can also be treated with CAR-T cell therapy. This increasing disease burden underscores the need for innovative and effective treatments like CAR-T cell therapy, driving market growth.
- Growing Awareness and Acceptance of Car-T Cell Therapy
The growing awareness and acceptance of CAR-T cell therapy as an effective treatment in the MEA, Saudi Arabia, and MEA regions are driven by various factors. These include heightened media coverage, educational efforts by healthcare organizations, and the sharing of success stories that highlight the therapy's effectiveness. Consequently, patients and healthcare providers are gaining a better understanding of CAR-T cell therapy's potential advantages, such as higher response rates and long-lasting remissions, especially in cases that are refractory or have relapsed. Additionally, regulatory approvals and endorsements in these regions have cemented CAR-T cell therapy's status as a legitimate and viable treatment option.
Opportunity
- The Extensive Pipeline of Car-T Cell Therapy
The extensive pipeline represents a wealth of opportunities for patients, healthcare providers, and the healthcare industry as a whole. This pipeline includes a range of CAR-T cell therapy products in various stages of development, from early preclinical Research to advanced clinical trials. The pipeline reflects ongoing innovation and investment in CAR-T cell therapy, with new products being developed to target different types of cancer and hematological disorders. Additionally, the pipeline includes products aimed at improving the safety, efficacy, and accessibility of CAR-T cell therapy, such as next-generation CAR-T cell therapies and off-the-shelf CAR-T cell products.
Restraints/Challenges
- High Cost of Car-T Cell Therapy
CAR-T cell therapy is a highly personalized and complex treatment that involves modifying a patient's immune cells to target cancer cells, making it a costly procedure. Factors contributing to this high cost include the specialized manufacturing process, extensive clinical monitoring, and infrastructure requirements. As a result, many patients, particularly those without adequate insurance coverage or financial resources, face challenges accessing this innovative therapy. The cost of clinical trials, regulatory compliance, and post-treatment monitoring further increases the overall expense, highlighting the financial burden for patients, especially those from lower-income backgrounds.
- Potential Risks and Adverse Effects of Treatment
CAR-T cell therapy, despite its promising efficacy, presents potential risks and side effects that pose challenges for patients and healthcare providers in the MEA, Saudi Arabia, and MEA regions. The most common side effects include cytokine release syndrome (CRS) and neurotoxicity. CRS, a significant adverse effect, occurs when infused CAR T cells recognize and attack cancer cells, leading to the release of cytokines like interleukin-6 (IL-6). This immune response causes systemic inflammation, manifesting in symptoms from mild fever and flu-like symptoms to potentially life-threatening complications like hypotension, respiratory distress, and multiorgan failure. CAR T-cell therapy can also trigger immune effector cell-associated neurotoxicity syndrome (ICANS), characterized by neurological symptoms such as confusion, seizures, and impaired speech. These side effects result from immune system overactivation and cytokine release, emphasizing the need for vigilant monitoring and prompt management to ensure patient safety and treatment efficacy.
Recent Developments
- In December 2023, Gilead Sciences, Inc. announced U.S. FDA has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy
- In May 2022, Bristol-Myers Squibb Company announced the approval of Opdivo plus Yervoy as a first line treatment for adult patients by Japan's Ministry of Health, Labour and Welfare. This may help the company to strengthen its product portfolio
- In February 2022, the FDA has approved CARVYKTI™ (ciltacabtagene autoleucel) from Janssen for treating adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, marking Janssen's inaugural cell therapy. This will underscore the dedication to advance their oncology treatment options
- In December 2021, Novartis AG has signed an agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), enhancing the company's immuno-oncology Research and development. This collaboration contributes to Novartis Oncology's broader initiative to advance innovation in cancer treatments by incorporating a potentially transformative therapy into its expanding immunotherapy platform
MEA CAR-T Cell Therapy Treatment Market Scope
The MEA CAR-T cell therapy treatment market is segmented into seven notable segments based on product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product
- Autologous CAR-T Cells
- Allogeneic CAR-T Cells
On the basis of product, the market is segmented into autologous CAR-T cells and allogeneic CAR-T cells.
Structure
- First Generation CAR-T Cells
- Second Generation CAR-T Cells
- Third Generation CAR-T Cells
- Fourth Generation CAR-T Cells
On the basis of structure, the market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells, and fourth generation CAR-T cells.
Targeted Antigens
- Antigens on Solid Tumors
- Antigens on Hematologic Malignancies
- Others
On the basis of targeted antigens, the market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others.
Brand
- Yescarta
- Kymriah
- Tecartus
- Others
On the basis of brand, the market is segmented into yescarta, kymriah, tecartus and others.
Therapeutic Application
- Hematological Malignancies
- Pancreatic Cancer
- Breast Cancer
- Lung Cancer
- Gastric Cancer
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma
- Acute Lymphoblastic Leukemia (ALL)
- Others
On the basis of therapeutic application, the market is segmented into diffuse large b-cell lymphoma, follicular lymphoma, Acute Lymphoblastic Leukaemia (ALL), mantle cell lymphoma, multiple myeloma, hematologic malignancies, lung cancer, chronic lymphocytic leukemia, gastric cancer, pancreatic cancer, breast cancer, and others.
End User
- Hospitals
- Specialty Clinics
- Others
On the basis of end user, the market is segmented into hospitals, specialty clinics and others.
Distribution Channel
- Hospitals Pharmacy
- Others
On the basis of distribution channel, the market is segmented into hospitals pharmacy and others.
MEA CAR-T Cell Therapy Treatment Market Regional Analysis/Insights
The MEA CAR-T cell therapy treatment market is segmented into seven notable segments based on product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel.
The countries covered in this market report are Saudi Arabia, South Africa, U.A.E., Israel, Kuwait, Egypt, and rest of Middle East and Africa.
Saudi Arabia is expected to dominate the MEA CAR-T cell therapy treatment market due to its advanced healthcare infrastructure, government support, growing medical tourism sector, research and development activities, and increasing demand for advanced treatments.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and MEA CAR-T Cell Therapy Treatment Market Share Analysis
The MEA CAR-T cell therapy treatment market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the market are Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Johnson & Johnson Services, Inc., among others.
SKU-